Tag Archives: Suraj Kalia

Northland Securities Keeps Their Hold Rating on Dexcom Inc (DXCM)

Northland Securities analyst Suraj Kalia maintained a Hold rating on Dexcom Inc (DXCM – Research Report) today and set a price target of $125. The company’s shares opened today at $123.03. Kalia commented: “We present here a comparative assessment of

Northland Securities Reaffirms Their Hold Rating on Medtronic (MDT)

Northland Securities analyst Suraj Kalia maintained a Hold rating on Medtronic (MDT – Research Report) today and set a price target of $84. The company’s shares opened today at $87.22. Kalia said: “We are updating our Medtronic model to better

Northland Securities Maintains Their Buy Rating on Varex Imaging Corporation (VREX)

In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on Varex Imaging Corporation (VREX – Research Report), with a price target of $42. The company’s shares opened today at $29.26. According to TipRanks.com, Kalia is

Northland Securities Maintains a Buy Rating on Strata Skin Sciences Inc (SSKN)

Northland Securities analyst Suraj Kalia maintained a Buy rating on Strata Skin Sciences Inc (SSKN – Research Report) today and set a price target of $7. The company’s shares opened today at $2.45. Kalia wrote: “We note that fully audited

BioLife Solutions (BLFS) Receives a Buy from Northland Securities

Northland Securities analyst Suraj Kalia maintained a Buy rating on BioLife Solutions (BLFS – Research Report) today and set a price target of $18. The company’s shares closed on Friday at $16.57. Kalia said: “We continue to believe BioLife is

Northland Securities Maintains Their Sell Rating on Intersect ENT (XENT)

In a report released today, Suraj Kalia from Northland Securities maintained a Sell rating on Intersect ENT (XENT – Research Report), with a price target of $20. The company’s shares closed yesterday at $33.15. Kalia wrote: “We were not allowed